Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetes

Endocrinology, Diabetes & Metabolism
Mariam AlatrachEugenio Cersosimo

Abstract

To determine the glucose-lowering mechanism of action and the effects of a quick-release bromocriptine-QR, a D2-dopamine agonist (Cycloset) on vascular function in patients with type 2 diabetes (T2D). Fifteen poorly controlled T2D treated with metformin plus glucagon-like peptide-1 receptor agonists (GLP-1RA) were studied after 4 months of Cycloset, 3.2 mg/d. Subjects received a 5-hour double-tracer (iv 3-3H-glucose and oral 14C-glucose) mixed meal test (MMT) to quantitate rates of endogenous glucose production (EGP), oral glucose appearance (RaO) and disappearance (Rd) pre- and post-Cycloset. Vascular assessments included 2-day continuous BP monitoring, reactive hyperaemia index (RHI) and arterial stiffness (AS). HbA1c decreased from 8.3 ± 0.3% to 7.7 ± 0.2% (P < 0.05), fasting plasma glucose did not change (143 ± 4 vs 147 ± 5) and mean plasma glucose during MTT decreased from 223 ± 3 to 210 ± 4 mg/dL (P < 0.05) after Cycloset. Basal EGP (2.2 ± 0.2 vs 2.1 ± 0.2 mg/kg min) was unchanged, but there was greater MMT suppression (1.1 ± 0.1 vs 0.7 ± 0.1, P < 0.05). After Cycloset, RaO declined from 2.0 ± 0.1 to 1.7 ± 0.2 mg/kg min and peripheral oral glucose appearance from 53.1 ± 3.2 to 44.4 ± 3.1 g (P < 0.01). There were no change...Continue Reading

References

Oct 18, 1979·The New England Journal of Medicine·D Parkes
Oct 23, 1986·The New England Journal of Medicine·P L LudmerP Ganz
Jan 1, 1988·Metabolism: Clinical and Experimental·E FerranniniR A DeFronzo
Jan 1, 1987·Diabetes/metabolism Reviews·T Shimazu
May 26, 1999·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·P W ScislowskiA H Cincotta
Jul 6, 2000·British Journal of Pharmacology·A S De VrieseP M Vanhoutte
Aug 11, 2000·Diabetes Care·H PijlR A DeFronzo
Mar 1, 2006·Diabetes/metabolism Research and Reviews·Eugenio Cersosimo, Ralph A DeFronzo
Mar 13, 2008·American Journal of Physiology. Endocrinology and Metabolism·Antonio CerveraEugenio Cersosimo
Mar 18, 2011·The Journal of Clinical Endocrinology and Metabolism·E CersosimoR A DeFronzo
Oct 4, 2014·American Journal of Physiology. Gastrointestinal and Liver Physiology·Luca Toti, R Alberto Travagli

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

Endo
ibm
Cycloset
PAT

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.